You are here

Eylea

Regeneron shoots for longer Eylea dosing interval in diabetic retinopathy with NIH data

Regeneron shoots for longer Eylea dosing interval in diabetic retinopathy with NIH data

Fierce Pharma

diabetic retinopathy

Flag link:

Bayer unveils first look at its post-Xarelto, post-Eylea life—and it's better than expected

Bayer unveils first look at its post-Xarelto, post-Eylea life—and it's better than expected

Fierce Pharma

Flag link:

Roche eyes FDA filing after bispecific matches Eylea again

Roche eyes FDA filing after bispecific matches Eylea again

Fierce Biotech

clinical trials

wet age-related macular degeneration

Flag link:

Bayer pharma chief admits to unfillable revenue gap despite potential blockbuster launches

Bayer pharma chief admits to unfillable revenue gap despite potential blockbuster launches

Fierce Pharma

Flag link:

Roche eyes an uncertain market for faricimab

Roche eyes an uncertain market for faricimab

EP Vantage

diabetic macular edema

Flag link:

Roche's bispecific matches Regeneron's Eylea in phase 3 trials

Roche's bispecific matches Regeneron's Eylea in phase 3 trials

Fierce Biotech

diabetic macular edema

clinical trials

bispecific antibodies

Flag link:

Novartis raises the temp on Eylea rivalry with head-to-head trial win for Beovu in diabetic macular edema

Novartis raises the temp on Eylea rivalry with head-to-head trial win for Beovu in diabetic macular edema

Endpoints

diabetic macular edema

Flag link:

Novartis says Beovu matched rival Eylea in visual acuity in eye disease

Novartis says Beovu matched rival Eylea in visual acuity in eye disease

Pharma Live

diabetic macular edema

clinical trials

Flag link:

Bayer's Eylea shows pandemic resilience, but major China price cut drags on business

Bayer's Eylea shows pandemic resilience, but major China price cut drags on business

Fierce Pharma

Flag link:

Regeneron vows ‘vigorous’ defense against allegations it paid kickbacks for eye drug

Regeneron vows ‘vigorous’ defense against allegations it paid kickbacks for eye drug

MedCity News

macular degeneration

Flag link:

Regeneron vows to fight DOJ lawsuit alleging charity donations were Eylea kickbacks

Regeneron vows to fight DOJ lawsuit alleging charity donations were Eylea kickbacks

Fierce Pharma

Flag link:

AsclepiX Emerges With $35M and an Eye Drug Challenger to Eylea, Lucentis

AsclepiX Emerges With $35M and an Eye Drug Challenger to Eylea, Lucentis

Xconomy

AsclepiX Therapeutics

wet age-related macular degeneration

retinal occulsion

Flag link:

Regeneron touts Eylea strength as Novartis rival falters, COVID-19 cuts demand

Regeneron touts Eylea strength as Novartis rival falters, COVID-19 cuts demand

Fierce Pharma

Flag link:

Does Regeneron Pharmaceuticals’ Winning Streak Signal Irrational Exuberance?

Does Regeneron Pharmaceuticals’ Winning Streak Signal Irrational Exuberance?

Motley Fool

Flag link:

Novartis knocked by safety scare

Novartis knocked by safety scare

EP Vantage

wet age-related macular degeneration

Flag link:

Regeneron’s Eylea delivers positive two-year results in PANORAMA trial

Regeneron’s Eylea delivers positive two-year results in PANORAMA trial

Pharmaceutical Business Review

diabetic neuropathy

clinical trials

Flag link:

Are Novartis and Regeneron seeing the same thing?

Are Novartis and Regeneron seeing the same thing?

BioPharma Dive

Flag link:

Biogen signs marketing deal for two ophthalmology biosimilars

Biogen signs marketing deal for two ophthalmology biosimilars

Pharmaforum

Samsung Bioepis

Flag link:

Regeneron profit beats expectations on Eylea, Dupixent strength

Regeneron profit beats expectations on Eylea, Dupixent strength

Yahoo/Reuters

Flag link:

Eylea could be in trouble, but that doesn't make Regeneron a buyer

Eylea could be in trouble, but that doesn't make Regeneron a buyer

Biopharma Dive

Flag link:

Pages